Literature DB >> 19268469

Expression of the kallikrein/kinin system in human anterior segment.

Jerry G Webb1, Xiaofeng Yang, Craig E Crosson.   

Abstract

Tissue kallikrein acts on the substrate, low molecular weight kininogen, to liberate bradykinin in a variety of tissues. Bradykinin stimulation of B(2) kinin receptors has been shown to initiate signaling in trabecular meshwork cells and increase conventional outflow facility. The objective of the present study was to determine if the components for kinin generation and response are expressed in tissues of the human anterior segment. Expression of mRNA encoding tissue kallikrein (KK), low molecular weight kininogen, and B(1) and B(2) kinin receptors was examined in human ciliary smooth muscle (CM), trabecular meshwork (TM) and non-pigmented epithelial (NPE) cells using RT-PCR. Expression of component proteins was also investigated by immunohistochemical analyses performed on parasagittal sections of human anterior segment and TM cells, and by immunoblot. KK mRNA was detected in NPE cells and in cultured CM and TM cells from multiple donors. Each cell type also expressed mRNAs encoding both B(1) and B(2) kinin receptors. Immunohistochemical analysis of KK protein in sectioned anterior segment supported the RT-PCR results. Intense KK immunofluorescence was observed in the epithelial lining of the ciliary body and KK protein was also detected in the ciliary muscle. KK protein expression within the TM was demonstrated by analyses of TM tissue and cultured TM cells. The presence of KK along with B(1) and B(2) receptor proteins was confirmed by immunoblots of cell lysates prepared from CM, NPE or TM cells. Finally, both CM and TM cells were found to possess enzymes for bradykinin inactivation. These data demonstrate that key components for kinin generation and regulation are localized within the human anterior segment. Further, multiple cell types express both B(1) and B(2) kinin receptors and are targets for kinin action. The results support the possibility that kinins produced within the eye may contribute to the regulation of aqueous outflow.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268469      PMCID: PMC2713788          DOI: 10.1016/j.exer.2009.02.016

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  23 in total

Review 1.  Bioregulation of kinins: kallikreins, kininogens, and kininases.

Authors:  K D Bhoola; C D Figueroa; K Worthy
Journal:  Pharmacol Rev       Date:  1992-03       Impact factor: 25.468

2.  The source of protein in the aqueous humor of the normal monkey eye.

Authors:  M F Barsotti; S P Bartels; T F Freddo; R D Kamm
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-03       Impact factor: 4.799

3.  Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine.

Authors:  Craig E Crosson; Carl F Sloan; Philip W Yates
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

4.  Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1.

Authors:  J A Finlay; J R Day; H G Rittenhouse
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

5.  Pharmacological characterization of bradykinin receptors coupled to phosphoinositide turnover in SV40-immortalized human trabecular meshwork cells.

Authors:  N A Sharif; S X Xu
Journal:  Exp Eye Res       Date:  1996-12       Impact factor: 3.467

6.  Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process.

Authors:  Shahid Husain; Farahdiba Jafri; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-05       Impact factor: 4.799

7.  Demonstration of an anterior diffusional pathway for solutes in the normal human eye with high spatial resolution contrast-enhanced dynamic MR imaging.

Authors:  Robert J Bert; Shelton D Caruthers; Hernan Jara; Jaroslaw Krejza; Elias R Melhem; Nancy H Kolodny; Samuel Patz; Thomas F Freddo
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-12       Impact factor: 4.799

8.  Kinin modulation of conventional outflow facility in the bovine eye.

Authors:  Jerry G Webb; Shahid Husain; Phillip W Yates; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2006-10       Impact factor: 2.671

9.  Bradykinin decreases outflow facility in perfused anterior segments and induces shape changes in passaged BTM cells in vitro.

Authors:  A Llobet; A Gual; J Palés; R Barraquer; E Tobías; J M Nicolás
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-01       Impact factor: 4.799

10.  Effect of matrix metalloproteinases activity on outflow in perfused human organ culture.

Authors:  J M Bradley; J Vranka; C M Colvis; D M Conger; J P Alexander; A S Fisk; J R Samples; T S Acott
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-12       Impact factor: 4.799

View more
  4 in total

1.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

2.  Bradykinin activation of extracellular signal-regulated kinases in human trabecular meshwork cells.

Authors:  Jerry G Webb; Xiaofeng Yang; Craig E Crosson
Journal:  Exp Eye Res       Date:  2011-03-21       Impact factor: 3.467

3.  Protein expression, biochemical pharmacology of signal transduction, and relation to intraocular pressure modulation by bradykinin B₂ receptors in ciliary muscle.

Authors:  Najam A Sharif; Shouxi Xu; Linya Li; Parvaneh Katoli; Curtis R Kelly; Yu Wang; Shutong Cao; Rajkumar Patil; Shahid Husain; Laura Klekar; Daniel Scott
Journal:  Mol Vis       Date:  2013-06-15       Impact factor: 2.367

4.  Characterizing the normal proteome of human ciliary body.

Authors:  Renu Goel; Krishna R Murthy; Srinivas M Srikanth; Sneha M Pinto; Mitali Bhattacharjee; Dhanashree S Kelkar; Anil K Madugundu; Gourav Dey; Sujatha S Mohan; Venkatarangaiah Krishna; Ts Keshava Prasad; Shukti Chakravarti; H C Harsha; Akhilesh Pandey
Journal:  Clin Proteomics       Date:  2013-08-01       Impact factor: 3.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.